ReviewAging medicine (Milton (N.S.W))2025
HDL-Apolipoprotein in Alzheimer's Disease Revisited: From Periphery to CNS.
Review in Aging medicine (Milton (N.S.W)), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Vascular contribution to cognitive impairment and dementia (VCID): proceedings of 2025 workshop of the Jackson Laboratory.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-density lipoprotein (HDL), as a crucial component of lipid metabolism, have roles in regulating Alzheimer's disease (AD) core pathology amyloid β (Aβ) and phosphorylated tau (p-tau) through its apolipoproteins, which are associated with brain structures, cognition, and risk of dementia. The pool of HDL apolipoproteins-in the brain and in the periphery-has its own distinct origin, composition, and regulatory mechanisms. It remains unclear whether these apolipoproteins in the periphery and CNS play distinct roles in the pathogenesis of AD. Specifically, this review focus on the distinct associations of apolipoprotein AI and apolipoprotein E-the major components of HDL in the blood and CSF-with pathological proteins, brain integrity, cognition, and dementia progression in AD. We summarize and examine the current state of knowledge on the values of these apolipoproteins in AD pathogenesis and clinical potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.